Evaluation of a new tablet formulation of deferasirox to reduce chronic iron overload after long-term blood transfusions

Overview of attention for article published in Therapeutics and Clinical Risk Management, February 2016

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (67th percentile)
Good Attention Score compared to outputs of the same age and source (78th percentile)

So far, Altmetric has seen 5 X posts from 5 X users, with an upper bound of 4,414 followers.

RT @Dr7alaAlanazi: Summary of pharmacokinetics/pharmacology of 2 deferasirox formulations, (Exjade®) and (Jadenu®). https://t.co/3gmhsf2dg…

RT @Clinicalpharma5: Summary of pharmacokinetics/pharmacology of 2 deferasirox formulations, (Exjade®) and (Jadenu®). https://t.co/3gmhsf2…

RT @Clinicalpharma5: Summary of pharmacokinetics/pharmacology of 2 deferasirox formulations, (Exjade®) and (Jadenu®). https://t.co/3gmhsf2…

Evaluation of a new tablet formulation of deferasirox https://t.co/DLko4UKxL1

Evaluation of a new tablet formulation of deferasirox https://t.co/CIeKct14sM